• AlzeCure received the full USD 12 million upfront payment from QuantumCell under the NeuroRestore Alzheimer’s platform licensing deal.
• Upfront includes a USD 7 million cash license fee, a USD 5 million direct investment, completing the initial transaction.
• Agreement provides milestone payments, tiered royalties from high single-digit to low double-digit percentages, valuing the deal above USD 2.2 billion excluding royalties.
• QuantumCell takes global rights to NeuroRestore, taking over clinical development, commercialisation, including lead candidate ACD856.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.